BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
Will Present on the Promise of Pluripotent Cells in Advanced
Therapeutics and the Company’s Plans to Develop Applications in Human
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 4, 2017--
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that Co-Chief Executive Officer Michael D.
West, Ph.D., is delivering a keynote presentation at the GTC
Bio Stem Cell Summit, on April 6 at the Hyatt
Regency in Boston, Massachusetts.
Titled “The Promise of Pluripotency in the Manufacture of Advanced
Cell-Based Therapeutics,” Dr. West’s keynote presentation is scheduled
for Thursday, April 6 at 10:40 a.m. EDT. It will provide an industry
update on therapeutic uses of human pluripotent cell-based regenerative
medicine, including BioTime’s clinical-stage OpRegen® and
Renevia® programs. Dr. West will also discuss the company’s
preclinical products in development for Type II diabetes and heart
disease, as well as the emerging field of induced tissue regeneration
(iTRTM) and their potential impact on the future of human
More information about the Stem Cell Summit is available at www.gtcbio.com/conferences/stem-cell-summit/.
More information on iTR is available via this video: https://www.youtube.com/watch?v=Owx2-jzgJHQ.
BioTime is a clinical-stage biotechnology company focused on developing
and commercializing products addressing degenerative diseases. Our
clinical programs are based on two platform technologies: pluripotent
stem cells and cell/drug delivery platform technologies. The foundation
of our core therapeutic technology platform is pluripotent cells that
are capable of becoming any of the cell types in the human body. The
foundation of our cell delivery platform is its HyStem® cell and drug
delivery matrix technology. The Company’s current clinical programs are
targeting three primary sectors, aesthetics, ophthalmology and cell/drug
delivery. We also have significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. (“Asterias”) and
OncoCyte Corporation (“OncoCyte”), which we founded and which, until
recently, were our majority-owned consolidated subsidiaries.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170404005517/en/
Source: BioTime, Inc.
EVC Group, Inc.
Brian Moore, 310-770-0389
Bill Douglass, 646-504-0890